• Arix Bioscience Plc’s (ARIX) portfolio company Aura Biosciences has reported further positive clinical data from its Phase 1b/2 clinical trial.
  • The trial was for assessing the safety and effectiveness of the company’s lead product candidate for the primary treatment of choroidal melanoma- light-activated AU-011.
  • The portfolio company is a front-runner in the development of new targeted treatments in ocular oncology.
  • On 16th October 2019, at the time of writing, GMT 12:45 PM, ARIX shares were trading at GBX 114.00, up by 6.00 points or 5.56 per cent against the previous day closing price.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK